EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Spectroscopic MRI-Based Biomarkers Predict Survival for Newly Diagnosed Glioblastoma in a Clinical Trial

Anuradha G Trivedi iD, Karthik K Ramesh, Vicki Huang iD, Eric A Mellon, Peter B Barker, Lawrence R Kleinberg iD, Brent D Weinberg iD, Hui-Kuo G Shu, Hyunsuk Shim

Cancers · 07.07.2023 · 15 (13) · 3524

DOI: 10.3390/cancers15133524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 07.07.2023. Verfasst von Anuradha G Trivedi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite aggressive treatment, glioblastoma has a poor prognosis due to its infiltrative nature. Spectroscopic MRI-measured brain metabolites, particularly the choline to N-acetylaspartate ratio (Cho/NAA), better characterizes the extent of tumor infiltration. In a previous pilot trial (NCT03137888), brain regions with Cho/NAA ≥ 2x normal were treated with high-dose radiation for newly diagnosed glioblastoma patients. This report is a secondary analysis of that trial where spectroscopic MRI-based biomarkers are evaluated for how they correlate with progression-free and overall survival (PFS/OS). Subgroups were created within the cohort based on pre-radiation treatment (pre-RT) median cutoff volumes of residual enhancement (2.1 cc) and metabolically abnormal volumes used for treatment (19.2 cc). We generated Kaplan–Meier PFS/OS curves and compared these curves via the log-rank test between subgroups. For the subgroups stratified by metabolic abnormality, statistically significant differences were observed for PFS (p = 0.019) and OS (p = 0.020). Stratification by residual enhancement did not lead to observable differences in the OS (p = 0.373) or PFS (p = 0.286) curves. This retrospective analysis shows that patients with lower post-surgical Cho/NAA volumes had significantly superior survival outcomes, while residual enhancement, which guides high-dose radiation in standard treatment, had little significance in PFS/OS. This suggests that the infiltrating, non-enhancing component of glioblastoma is an important factor in patient outcomes and should be treated accordingly.

Schlagwörter

Stichwörter der Autor:innen

dose-escalationglioblastomaradiation therapyspectroscopic MRIsurvival biomarkers

Autor:innen und Institutionen

  • Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA 30332, USA.
  • Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 45056, USA.
  • Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD 21218, USA.
  • Department of Radiation Oncology, Johns Hopkins University, Baltimore, MD 21218, USA.
  • Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.

ORCID-Profile: Anuradha G Trivedi, Vicki Huang, Lawrence R Kleinberg, Brent D Weinberg

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIH

Zitieren

APA

Trivedi, A. G., Ramesh, K. K., Huang, V., Mellon, E. A., Barker, P. B., Kleinberg, L. R., Weinberg, B. D., Shu, H. G., & Shim, H. (2023). Spectroscopic MRI-Based Biomarkers Predict Survival for Newly Diagnosed Glioblastoma in a Clinical Trial. Cancers, 15(13), 3524. https://doi.org/10.3390/cancers15133524

Vancouver

Trivedi AG, Ramesh KK, Huang V, Mellon EA, Barker PB, Kleinberg LR, et al. Spectroscopic MRI-Based Biomarkers Predict Survival for Newly Diagnosed Glioblastoma in a Clinical Trial. Cancers. 2023;15(13):3524. doi:10.3390/cancers15133524

BibTeX
@article{Trivedi2023,
  author = {Trivedi, Anuradha G and Ramesh, Karthik K and Huang, Vicki and Mellon, Eric A and Barker, Peter B and Kleinberg, Lawrence R and Weinberg, Brent D and Shu, Hui-Kuo G and Shim, Hyunsuk},
  title = {Spectroscopic MRI-Based Biomarkers Predict Survival for Newly Diagnosed Glioblastoma in a Clinical Trial},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {13},
  pages = {3524},
  doi = {10.3390/cancers15133524}
}
Kostenlos starten →